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Abstract Hereditary angioedema (HAE), a rare autoso-
mal dominant genetic disorder, is caused by a deficiency in
functional C1 esterase inhibitor (C1-INH). This potentially
life-threatening condition manifests as recurrent attacks of
subcutaneous and submucosal swelling of the skin, gas-
trointestinal tract and larynx. The management of HAE
includes treatment of acute episodes, short-term prophy-
laxis in preparation for exposure to known triggers and
long-term prophylaxis to decrease the incidence and
severity of HAE attacks. Four products are approved in the
USA for the treatment of acute attacks of HAE, including
one human plasma-derived C1-INH therapy, a recombinant
human C1-INH product (rhC1-INH), a plasma kallikrein
inhibitor and a bradykinin B2 receptor antagonist. In
addition, one human plasma-derived C1-INH therapy and
danazol are approved for prophylaxis of HAE attacks.
rhC1-INH, extracted from the milk of transgenic rabbits, is
a glycoprotein of 478 amino acids with an identical amino
acid sequence to the endogenous human C1-INH protein.
Population pharmacokinetic analysis of rhC1-INH supports
an intravenous dosing strategy of 50 U/kg (maximum
4200 U). The safety and efficacy of rhC1-INH in the
treatment of acute attacks in patients with HAE were
demonstrated in three randomized, double-blind, placebo-
controlled studies and two open-label extension studies. In
a pilot prophylaxis study, weekly administration of rhC1-
INH 50 U/kg for 8 weeks reduced the incidence of HAE
attacks and was well tolerated. Administration of rhC1-
INH has not been associated with the development of anti-
drug antibodies or antibodies to anti-host-related
impurities.
Key Points
Hereditary angioedema (HAE) is a potentially life-
threatening autosomal dominant disorder caused by
deficiency of functional C1 esterase inhibitor (C1-
INH).
Four products are approved for the treatment of acute
HAE in the USA, including one human plasma-
derived C1-INH therapy, a recombinant human C1-
INH product (rhC1-INH), a plasma kallikrein
inhibitor and a bradykinin B2 receptor antagonist.
Another human plasma-derived C1-INH therapy and
danazol are approved for HAE prophylaxis.
In randomized, controlled trials and open-label
extension studies, rhC1-INH has demonstrated
efficacy and safety for the treatment of acute attacks
of HAE, with preliminary data showing possible
utility for long-term HAE prophylaxis.
1 Introduction
Hereditary angioedema (HAE) is a rare autosomal domi-
nant genetic disease caused by a quantitative or qualitative
deficiency of C1 esterase inhibitor (C1-INH) [1, 2]. The
disease is characterized by recurrent episodes (attacks) of
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subcutaneous and submucosal swelling involving the skin,
gastrointestinal tract and larynx [1–3]. Swelling of the
larynx can cause fatal asphyxiation [2]. Although the fre-
quency of attacks can vary considerably in untreated
patients (every 7–14 days on average), individual HAE
attacks generally follow a predictable clinical course of
symptoms developing gradually during the first 24 h and
then subsiding during the subsequent 48–72 h [1]. The
prevalence of HAE is unclear; however, it is estimated to
affect 1 in 50,000–100,000 individuals globally [4–6]. The
onset of symptoms typically begins during childhood;
symptoms often worsen during puberty, and HAE attacks
generally continue throughout the life of the patient [1].
HAE episodes usually occur without a predictable trigger;
however, attacks can be precipitated by minor surgical or
dental procedures or trauma, infection and stress [7].
C1-INH is a serine protease inhibitor, which directly or
indirectly inhibits several proteases associated with HAE
attacks (Fig. 1) [1, 8]. C1-INH is a major inhibitor of
several complement proteases such as C1r and C1s [1, 9,
10] and contact proteases, including factor XIIa [1, 11] and
kallikrein [1, 12], and a minor inhibitor of fibrinolytic
proteases such as plasmin and factor XIa [1, 13, 14]. In
patients with HAE, uninhibited activation of the contact
Fig. 1 Schematic representation of the pathways inhibited by C1
esterase inhibitor (C1-INH). C1-INH inhibits proteases in the
complement, contact activation and fibrinolytic pathways. In hered-
itary angioedema, uninhibited activation of the contact pathway
because of deficiency in functional C1-INH results in unregulated
cleavage of high molecular weight kininogen by kallikrein, leading to
generation of excessive free bradykinin, which is a potent vasoactive
peptide. Proteolytic activities are indicated with green arrows, and
steps inhibited by C1-INH are shown by red bars. From Zuraw [1]. 
2008 Massachusetts Medical Society. Reprinted with permission from
Massachusetts Medical Society [1]
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pathway due to insufficient levels of functional C1-INH
results in unregulated cleavage of high molecular weight
kininogen by kallikrein, leading to generation of excessive
free bradykinin [1, 15]. Bradykinin is a potent vasoactive
peptide, which mediates increased capillary permeability
and oedema [15, 16]. There are three subtypes of HAE,
generally classified according to associated levels and
functional activity of C1-INH [1]. Type I is the most
prevalent, accounting for *85 % of cases, and is defined
by a quantitative deficiency of C1-INH protein [1, 17].
Type II HAE (*15 % of cases) is associated with normal
levels of C1-INH but deficient functional C1-INH activity,
as the protein does not function properly. HAE with normal
C1-INH (historically referred to as type III) is a rare, lar-
gely oestrogen-dependent form of HAE, mostly affecting
females; the quantitative and functional levels of C1-INH
are normal but patients experience angioedema attacks [1];
the pathophysiology of this HAE subtype is poorly
understood.
The management of HAE includes treatment of acute
attacks, short-term or procedural prophylaxis (e.g. before
dental procedures, minor surgery or endoscopy) and long-
term prophylaxis to minimize the frequency and severity of
recurrent attacks [4, 18, 19]. Until 2008, management of
HAE in the USA was limited to the use of fresh frozen
plasma, antifibrinolytic agents, synthetic attenuated
androgens and supportive care. Six products are currently
approved by the US Food and Drug Administration (FDA)
for the acute treatment (n = 4) or prophylaxis (n = 2) of
HAE (Table 1) [20–26]. These products include three C1-
INH replacement therapies (two human plasma-derived
C1-INH preparations [Cinryze (Shire ViroPharma Inc.,
Lexington, MA, USA) and Berinert (CSL Behring
GmbH, Marburg, Germany)] and one recombinant human
C1-INH preparation [rhC1-INH]), a plasma kallikrein
inhibitor (ecallantide), a bradykinin B2 receptor antagonist
(icatibant) and a synthetic attenuated androgen (danazol).
In Europe, human plasma-derived C1-INH products have
been used for more than three decades for the treatment of
acute HAE, and icatibant and rhC1-INH have been
approved since 2008 and 2010, respectively [27–29].
Although human plasma-derived C1-INH products have
been available globally for many years, there are concerns,
as with any plasma-derived product, about the potential
Table 1 US Food and Drug Administration (FDA)-approved agents for the treatment of hereditary angioedema (HAE) [20–26]
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should be minimized by decreasing dosage as
tolerated based on clinical response and
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Prevention of angioedema attacks
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30 mg abdominal injection every 6 h
(maximum, 3 doses every 24 h)
Can be self-administered








50 IU/kg (\84 kg body weight) and 4200 IU
(C84 kg body weight); B2 doses every 24 h
Can be self-administered
Acute attacks in adults and
adolescents (investigated in
patients aged C13 years) with
HAE
2014
IV intravenous, rhC1-INH recombinant human C1 esterase inhibitor, SC subcutaneous
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risk of transmission of blood-borne pathogens, as well as
supply issues [27].
This review provides comprehensive information on the
synthesis, pharmacokinetics and pharmacodynamics, effi-
cacy and safety of intravenous rhC1-INH for the treatment
of patients with HAE. In addition, the product character-
istics and safety profile of rhC1-INH are compared with
those of human plasma-derived C1-INH products,
ecallantide and icatibant. The articles included in this
narrative review were identified by a systematic search of
PubMed using (‘‘recombinant c1 esterase inhibitor’’ OR
‘‘recombinant C1 inhibitor’’) AND ‘‘hereditary angioe-
dema’’ keywords for articles in English and consultation of
recent review articles for general information on HAE
prevalence, aetiology and treatment options. Bibliogra-




rhC1-INH, a single-chain glycoprotein of 478 amino acids,
is derived from milk of transgenic rabbits ([99 % purity)
using a 3-step Sepharose-based purification procedure
including cation exchange chromatography, anion
exchange chromatography and affinity chromatography
[30, 31]. The recombinant human formulation was devel-
oped as an alternative to human plasma-derived C1-INH to
eliminate the risk of transmission of human blood-borne
pathogens, as well as to provide a reliable and scalable
supply that is not dependent on human plasma donors [8].
It is approved in the European Union and the USA for
adults and adolescents (evaluated in individuals C13 years
of age) for the treatment of acute angioedema attacks in
patients with HAE due to C1-INH deficiency [24, 29]. The
amino acid sequence of rhC1-INH is identical to that of
endogenous human C1-INH but has differences in glyco-
sylation patterns [30].
2.2 Pharmacokinetics and Pharmacodynamics
Population pharmacokinetics of rhC1-INH were evaluated
by pooling data from six clinical studies in which blood
samples were taken before and after intravenous adminis-
tration of the drug in healthy volunteers, asymptomatic
patients with HAE and patients with acute HAE attacks
(294 administrations in 133 individuals; dose range
6.25–121 U/kg) [32]. In this analysis, the half-life of rhC1-
INH was determined to be *3 h for a 100 U/kg dose
(similar to the mean half-life of 2.4 h reported for a
50 U/kg dose [24]); this interval is shorter than the
intervals reported for human plasma-derived C1-INH prod-
ucts, which range from22 to 56 h [8, 20, 21, 32–34].Ahigher
degree of glycosylation on the rhC1-INH protein results in
faster clearance of rhC1-INH from the circulation compared
with human plasma-derived C1-INH protein [32].
The pharmacokinetic profile of rhC1-INH was similar
after single and multiple dosing [32]. The final estimation
of the volume of distribution was 2.9 L, which is consistent
with the reported volume of plasma [32, 35]. Based on
these analyses, a dosing scheme of 50 U/kg of rhC1-INH
up to 84 kg body weight and a fixed dose of 4200 U for
patients weighing C84 kg (Fig. 2) [32] was deemed
appropriate to restore functional C1-INH levels. In a sep-
arate pharmacokinetic study, 12 asymptomatic patients
with HAE receiving 6.25–100 U/kg of rhC1-INH on two
occasions exhibited dose-dependent biological C1-INH
activity with increasing plasma complement C4 levels
(twofold after 12 h of administration of rhC1-INH 100 U/kg)
and decreasing levels of its cleaved form [31].
3 Clinical Efficacy
3.1 Acute Attacks
The efficacy of rhC1-INH in the treatment of acute attacks
in patients with HAE was evaluated in three randomized,
double-blind, placebo-controlled studies and two open-la-
bel extension (OLE) studies (Table 2) [36–40]. Two
























Fig. 2 Simulation of peak recombinant human C1 esterase inhibitor
(rhC1-INH) concentrations for levels of the proposed dosing regimen
(50 U/kg for up to 84 kg body weight and a fixed dose of 4200 U for
patients with body weight[84 kg). The 25th and 75th percentiles
with the median values are represented as boxes; ends of whiskers
represent 1.5 times the interquartile ranges (from the 25th and 75th
quartiles). Any observations beyond 1.5 times the interquartile ranges
are indicated as open circles, and the dashed line represents the lower
limit of normal C1-INH (0.7 U/mL). Reprinted from Farrell et al.



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































independent, randomized, double-blind, placebo-controlled
studies were similarly designed: a North American study
(C1 1205-01; 50 U/kg [n = 12] or 100 U/kg [n = 13]
rhC1-INH vs placebo [n = 13]) and a European study (C1
1304-01; 100 U/kg rhC1-INH [n = 16] vs placebo
[n = 16]) [36]. Patients included in these trials presented
with onset of HAE symptoms within\5 h of enrolment
and had an overall severity score of C50 mm on a visual
analogue scale (VAS) [36]. The primary efficacy endpoint
was the median time to onset of symptom relief (C20 mm
decrease from baseline in the VAS score for two consec-
utive readings) [36]. A pooled analysis of the two studies
indicated a significantly faster onset of symptom relief for
both doses of rhC1-INH, 50 U/kg (122 min; 95 % confi-
dence interval [CI] 72–136; P = 0.013) and 100 U/kg
(66 min; 95 % CI 61–122; P\ 0.001), versus placebo
(495 min; 95 % CI 245–520). Although the median time to
onset of relief was different for 50 versus 100 U/kg in the
pooled analysis, the 95 % CIs overlapped for these dosing
regimens, and Kaplan–Meier plots of both doses showed
no significant difference in response. Median time to onset
of relief at different anatomical locations (most attacks
were peripheral or abdominal) with both doses of rhC1-
INH (range 50–124 min) was faster than with placebo
(range 243–560 min). In addition, treatment with both
doses of rhC1-INH significantly reduced the median time
to minimal symptoms compared with placebo (247, 266
and 1210 min for 50 and 100 U/kg rhC1-INH and placebo,
respectively; P B 0.001 vs placebo for both rhC1-INH
doses) [36].
The efficacy of rhC1-INH observed in the double-blind
studies was maintained during treatment of subsequent
HAE attacks during the OLE studies [37, 38]. For the first
five HAE attacks during the North American OLE study
(n = 62), the median time to onset of symptom relief
([20 mm decrease from baseline in the VAS score) ranged
from 37 to 67 min and the median time to minimal
symptoms (VAS score \20 mm) ranged from 120 to
244 min [37]. Few attacks (10.0 %) required treatment
with a second dose, and of these, most were oro-facial-
pharyngeal-laryngeal attacks. Like the North American
OLE study, the European OLE study (n = 57) supported
the continued efficacy of rhC1-INH after repeated treat-
ments for subsequent HAE attacks. The median times to
onset of symptom relief (C20 mm decrease from baseline
in the VAS score) for HAE attack numbers 1 through 5
were 60, 65, 120, 60 and 61 min, respectively [38]. By
anatomical site, the fastest median time to symptomatic
relief occurred with abdominal attacks (33 min), followed
by peripheral attacks (61 min), oro-facial-pharyngeal-la-
ryngeal attacks (120 min) and genitourinary attacks
(480 min). The faster response observed with abdominal
attacks compared with peripheral attacks is theorized to be
due to faster resorption of fluid in the submucosal tissue
compared with subcutaneous tissue.
In addition, a phase 3, randomized, double-blind, pla-
cebo-controlled study was conducted as part of an FDA
biologics license application (Study C1 1310) [39]. The
study evaluated the efficacy and safety of rhC1-INH
(50 U/kg for patients weighing \84 kg and 4200 U for
patients weighing C84 kg) for the treatment of acute
attacks in patients with HAE. The most common primary
attack locations (anatomical locations with the highest
overall-severity baseline VAS scores) in this study were
peripheral (44 %) and abdominal (37 %) [39]. The primary
endpoint, median time to onset of symptom relief, was
significantly shorter in patients who received rhC1-INH
compared with placebo, regardless of the instrument used
to assess efficacy: the treatment effect questionnaire (TEQ)
score (90 vs 152 min, respectively; P = 0.031; Fig. 3) [39]
or the VAS score (75 vs 303 min; P = 0.003). Treatment
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Fig. 3 Kaplan–Meier plot of time to onset of symptom relief based
on Treatment Effect Questionnaire results. In this phase 3, random-
ized, double-blind, placebo-controlled study, patients with an acute
attack of hereditary angioedema were treated with recombinant
human C1 esterase inhibitor (rhC1-INH) (50 U/kg for patients
weighing \84 kg and 4200 U for patients weighing C84 kg). The
censor flags indicate time points at which data were censored: patients
who did not achieve the beginning of persistent symptom relief during
the 24-h assessment period were censored at the last assessment time
point (i.e. excluded from further efficacy analyses). Patients who
received prohibited medications or open-label rescue rhC1-1NH
before perceiving persistent symptom relief were censored at the last
time point at which the Treatment Effect Questionnaire score was
assessed before these medications were administered. Patients who
did not experience minimal symptoms during the assessment period
also were censored at the last assessment time point. Reprinted from
Riedl [39], Copyright 2014, with permission from American College
of Allergy, Asthma & Immunology
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symptoms compared with placebo (303 vs 483 min,
respectively [TEQ]; P = 0.078; or 240 vs 362 min,
respectively [VAS]; P = 0.005).
Overall, the efficacy results from three randomized,
double-blind, placebo-controlled studies and two OLE
studies using a validated VAS instrument showed a con-
sistent benefit of rhC1-INH in the treatment of acute
angioedema attacks in patients with HAE [36–39].
Although direct comparisons are not possible because of
study design and outcome measure differences, the efficacy
data for rhC1-INH in the treatment of acute attacks of HAE
appear to be similar to results observed in randomized,
placebo-controlled trials of human plasma-derived C1-INH
products [41–43]. The median times to onset of patient-
reported symptom relief were 30 min with Berinert
20 U/kg versus 90 min with placebo (P = 0.0025) [41]
and 120 min with Cinryze 1000 U versus[240 min with
placebo (P = 0.02) [42].
While not the focus of this review, it should be noted
that the kinin pathway modulators ecallantide and icatibant
are available as subcutaneous treatment options for acute
HAE attacks. Ecallantide, a plasma kallikrein inhibitor, has
been evaluated in two randomized, double-blind, placebo-
controlled, phase 3 studies [44, 45]. In one study (n = 72),
ecallantide 30 mg significantly reduced a composite treat-
ment outcome score (range -100 [significant symptom
worsening] to ?100 [significant symptom improvement])
at 4 h postdose versus placebo (median score 50.0 vs 0.0,
respectively; P = 0.004; primary endpoint) [44]. There
was no significant difference in the median time to sig-
nificant improvement (patient-reported outcome of overall
symptoms ‘‘a lot better or resolved’’) between ecallantide
(165.0 min) and placebo ([240 min; P = 0.1). In a sec-
ond study (n = 96), a significant improvement from
baseline in the mean symptom complex severity score
(1 = mild; 2 = moderate; 3 = severe) 4 h postdose was
reported for ecallantide 30 mg (-0.8 ± 0.6) versus pla-
cebo (-0.4 ± 0.8; P = 0.01; primary endpoint) [45].
Ecallantide is licensed in the USA for the treat-
ment of acute attacks of HAE in patients 12 years and older
[46].
Icatibant, a bradykinin B2 receptor antagonist, has been
evaluated in three randomized, double-blind, phase 3 trials
[47, 48]. One of the phase 3 studies (n = 56) failed to meet
the primary endpoint. No significant difference between
subcutaneous icatibant 30 mg and placebo in the median
time to clinically significant relief (C30 % decrease from
baseline in the VAS score; primary endpoint) of the index
symptom was observed (2.5 vs 4.6 h, respectively;
P = 0.1), while in a second study (n = 74) of icatibant
30 mg versus tranexamic acid 3 g/day, the same primary
endpoint was achieved (2.0 vs 12.0, respectively;
P\ 0.001) [47]. Given the failure to achieve the primary
endpoint in the first study, another placebo-controlled study
(n = 88) was conducted [48]. In this third study, icatibant
30 mg significantly reduced the median time to cutaneous
or abdominal attack symptom relief (50 % reduction from
baseline in severity, assessed by a three-symptom [skin
swelling, skin pain, abdominal pain] composite VAS score)
versus placebo (2.0 vs 19.8 h; P\ 0.001; primary end-
point). Icatibant is licensed in*40 countries, including the
USA, for the treatment of acute HAE attacks in patients
18 years and older [23].
3.2 Prophylaxis
The efficacy of rhC1-INH (50 U/kg once-weekly admin-
istration) for long-term prophylaxis in patients with HAE
experiencing frequent attacks (C1 attack every 2 weeks)
was evaluated in a pilot open-label study (n = 25) for
8 weeks (Table 2) [40]. The mean breakthrough attack rate
was 0.4 attacks per week over the 8-week treatment period.
Despite its short half-life, rhC1-INH appeared beneficial
for long-term prophylaxis in patients with HAE. However,
additional rigorous controlled studies are necessary to
determine the true efficacy of rhC1-INH for long-term
HAE prophylaxis [25, 42, 49]. Both human plasma-derived
C1-INH products have been used for short-term and long-
term prophylaxis in HAE as reported in uncontrolled and
observational studies [19, 25]. In addition, in a randomized,
double-blind, placebo-controlled, crossover study (n = 22)
in which Cinryze 1000 U or placebo was administered
every 3–4 days for 12 weeks, with open-label Cinryze as
rescue treatment for acute attacks, the frequency of HAE
attacks was reduced by *50 % during Cinryze versus
placebo administration [42]. Currently, in the USA, Cin-
ryze is the only C1-INH agent approved for the routine
prophylaxis of HAE attacks. A 12-week, dose-escalation
study in 2014 indicated that some patients may require up
to 2500 U of Cinryze every 3–4 days to prevent acute
HAE attacks [49].
4 Safety and Tolerability
4.1 Adverse Events
Safety data from randomized, controlled studies and OLE
studies with rhC1-INH (Table 2) support a favourable
safety profile [36–40], and results were similar to those
reported in clinical trials of human plasma-derived C1-INH
products [41, 42]. Pooled safety data from the two ran-
domized, placebo-controlled studies indicated that 33, 24
and 48 % of patients receiving 50 U/kg rhC1-INH,
100 U/kg rhC1-INH and placebo, respectively, had C1
adverse event (AE) [36]. Headache was the most common
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AE in the rhC1-INH 100 U/kg group (10 %) and the pla-
cebo group (14 %); no headaches were reported in the
50 U/kg group. Headache and vertigo were considered
related to rhC1-INH treatment. Colitis was reported in one
patient after 31 days of rhC1-INH 100 U/kg treatment; it
was not considered by the investigators to be related to the
study drug and was the only serious AE reported in the
rhC1-INH groups. In an additional phase 3, randomized,
controlled study, 7 and 22 % of patients reported C1 AE in
the rhC1-INH and placebo groups, respectively, within
72 h of dosing; one serious AE of abdominal hernia in the
rhC1-INH group after 70 days of dosing was considered
unrelated to the study drug [39].
Safety data reported in the OLE studies were generally
similar to those reported in the randomized controlled
studies. In the North American OLE study, 63 % of
patients reported C1 AE, and most AEs were mild to
moderate in intensity [37]. Twenty serious AEs were
reported in ten patients, of which 13 AEs in eight patients
were HAE attacks; seven serious AEs reported in four
patients included vertigo, pneumonia, urosepsis (two epi-
sodes) and itching of the lips and soft palate with no signs
of a systemic allergic reaction. In the European OLE study,
additional dose(s) of rhC1-INH administered in a subset of
patients did not increase the incidence of AEs (28 and
26 % of patients receiving one dose or C1 dose of rhC1-
INH 2100 U, respectively), and no serious AEs were
reported in this study [38]. In the long-term prophylaxis
study with rhC1-INH, 52 % of patients reported C1 AE;
two AEs (acute appendicitis and laryngeal oedema) were
serious, but neither was considered related to the study
drug [40].
An increased risk of thromboembolic complications has
been reported with off-label, high-dose use of human
plasma-derived C1-INH products, potentially mediated
through increased levels of C1-INH, which can interact
with fibrinolytic proteases, leading to a risk of throm-
boembolic adverse effects [20, 21, 50]. However, clinical
studies with rhC1-INH have not suggested an increased
risk of thromboembolic complications [36–40]. Post hoc
analyses of the effects of rhC1-INH on coagulation and
fibrinolysis in patients with HAE who participated in the
randomized, placebo-controlled North American study
further supported that rhC1-INH treatment had no pro-
thrombotic effects in patients with HAE receiving up to
100 U/kg [36, 51].
Regarding the safety and tolerability profile of other
acute HAE therapies, the most common AEs reported for
ecallantide (n = 255; pooled data) were headache (16 %),
nausea (13 %), fatigue (12 %) and diarrhoea (11 %) [22].
Anaphylaxis has been reported in 4.0 % of patients treated
with ecallantide; thus, a boxed warning in the prescribing
information indicates that ecallantide should only be
administered by a healthcare provider with appropriate
support to manage cases of anaphylaxis, and that patients
should be closely monitored due to the similarity between
symptoms of hypersensitivity reaction and an HAE attack
[22]. Unlike with ecallantide, no events of anaphylaxis
have been reported in clinical trials of icatibant [23]. The
most commonly reported AEs with icatibant (n = 77;
pooled data) have been injection-site reactions (97 %),
pyrexia (4 %) and increased transaminase levels (4 %)
[23].
4.2 Immunogenicity
Therapeutic proteins have the risk of eliciting an antibody
response to the protein itself (anti-drug antibodies) or to
impurities originating from the biological system used to
produce the protein (e.g. anti-host-related impurities [anti-
HRI]) [52]. Because rhC1-INH is derived from the milk of
transgenic rabbits and contains a small percentage
(\0.002 %) of HRI, it is contraindicated in patients with
known or suspected allergy to rabbits or rabbit-derived
products [24]. Data from clinical trials support that rhC1-
INH has a low potential to induce anti-drug antibodies or
anti-HRI responses in patients with HAE [52]. In a pooled
analysis of five rhC1-INH clinical studies in symptomatic
patients with HAE (n = 155; 424 administrations), 1.5 and
1.3 % of all pre-exposure and postexposure tests, respec-
tively, were above the cutoff level (set using plasma
samples from C50 patients with HAE naı¨ve to rhC1-INH)
of the screening assays for anti-C1-INH antibodies. How-
ever, these results were not accompanied by any clinical
symptoms indicating hypersensitivity or any apparent
changes in rhC1-INH efficacy. Anti-HRI antibodies were
above the cutoff level in 0.7, 1.9 and 1.6–3.1 % of the
screening assay tests before exposure, at 90 days after the
first exposure and after repeat rhC1-INH treatment (22 or
90 days after repeat exposure), respectively. As with the
anti-C1-INH antibody results, positive anti-HRI antibody
results were not accompanied by clinical symptoms of
hypersensitivity reactions.
The potential of rhC1-INH to induce immunoglobulin E
(IgE) antibodies against rabbit milk proteins and other
allergens was tested by a retrospective analysis of eight
rhC1-INH clinical studies (130 patients with HAE and 14
healthy volunteers; 300 administrations) [53]. Approxi-
mately 50 % of individuals were exposed more than once
to rhC1INH (median, 2). A total of 24 individuals tested
positive for select animal allergens (e.g. rabbit, cow, cat or
horse dander) prior to rhC1-INH exposure. Five of these
individuals had pre-existing anti-rabbit-epithelium IgE
antibodies, and one of them experienced an anaphylactic
reaction, the only such case observed in this study popu-
lation. This individual received antihistamine and inhaled
Recombinant Human C1 Esterase Inhibitor 415
b-agonist therapy, with normalization of her condition
within 1 h. None of these individuals had an increase in
anti-rabbit IgE levels after rhC1-INH exposure. Of the 19
of 24 individuals who had pre-exposure positivity for select
animal allergens other than rabbit, three (15.8 %) devel-
oped anti-rabbit IgE antibodies after rhC1-INH exposure;
none of these individuals experienced allergic-type reac-
tions during treatment with rhC1-INH.
5 Conclusions
HAE is a rare genetic disorder caused by a deficiency in
functional C1-INH, and rapid replacement of functional
C1-INH is a treatment strategy for managing HAE attacks.
The recombinant technology used for the production of
rhC1-INH addresses plasma supply concerns and potential
risks for transmissible infections associated with human
plasma-derived C1-INH products. Global, multicentre
clinical studies have demonstrated that rhC1-INH is effi-
cacious and well tolerated for the treatment of acute HAE
attacks. Treatment with rhC1-INH has been shown to
produce a rapid and sustained improvement in attack-re-
lated clinical symptoms. Preliminary data also suggest that
rhC1-INH may be beneficial as long-term prophylaxis in
patients with HAE; however, additional controlled studies
are needed to validate this finding. A phase 2 prophylaxis
study is ongoing, with anticipated completion in 2015.
Currently, the clinical management of HAE involves
individualized patient treatment plans using licensed
medication options to terminate attacks, with additional
prophylactic therapy in selected patients. The rapid onset
of relief, durable efficacy and favourable safety profile
associated with rhC1-INH treatment support its use in
acute HAE treatment plans.
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